Why Choose Us?
Let China use globally innovative vaccines, and let the world use high-quality vaccines from China!
Strong Corporate Strength
The registered capital is 360 million yuan, the investment in Phase I project is 500 million yuan, the investment in Phase II project is 500 million yuan, and the new investment in Phase III is 2 billion yuan
Products & Services
Committed to the research and development, registration and application, industrial production and sales of innovative vaccines for human use, targeting international standards, and conducting independent innovative research and development.
Scientific Research Capability
Shanghai/Taizhou R&D Center and pilot platform are promoting multiple viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccine pipelines simultaneously.
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Quadrivalent Subunit Influenza Vaccine（0.5ml）
The launch ceremony of the quadrivalent influenza virus subunit vaccine Huierkangxin was successfully held!
The launch meeting of the safety evaluation research project for the tetravalent influenza virus subunit vaccine after its launch was a complete success
Launch | Zhonghui Biological Tetravalent Influenza Virus Subunit Vaccine Approved for Launch